Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $48.00 at Truist Financial

Collegium Pharmaceutical (NASDAQ:COLL) had its target price upped by Truist Financial from $45.00 to $48.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

COLL has been the topic of a number of other research reports. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Finally, HC Wainwright boosted their price target on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the company a “buy” rating in a research report on Friday. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.25.

Collegium Pharmaceutical Stock Up 4.0%

NASDAQ COLL traded up $1.64 on Friday, hitting $42.30. 864,974 shares of the stock were exchanged, compared to its average volume of 414,440. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $43.06. The company has a 50-day moving average price of $35.70 and a 200-day moving average price of $32.76. The company has a quick ratio of 1.10, a current ratio of 1.54 and a debt-to-equity ratio of 2.94. The company has a market cap of $1.33 billion, a PE ratio of 26.27 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. The business had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. Sell-side analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the sale, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $38.42, for a total transaction of $671,504.76. Following the transaction, the executive vice president owned 70,264 shares in the company, valued at approximately $2,699,542.88. This trade represents a 19.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 74,133 shares of company stock worth $2,899,504 over the last three months. 2.51% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rubric Capital Management LP increased its holdings in shares of Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after purchasing an additional 157,743 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its position in Collegium Pharmaceutical by 1.4% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,371,448 shares of the specialty pharmaceutical company’s stock worth $40,938,000 after buying an additional 19,568 shares during the period. Emerald Advisers LLC increased its holdings in Collegium Pharmaceutical by 1.3% in the second quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock valued at $24,766,000 after buying an additional 11,074 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Collegium Pharmaceutical by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock valued at $23,075,000 after acquiring an additional 14,709 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Collegium Pharmaceutical by 18.1% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company’s stock worth $21,309,000 after acquiring an additional 109,655 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.